Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 2/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23089346 | 0.81 | MAP4K4 (0.50) | MAP4K4OPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL23089343 | 0.81 | MAP4K4 (0.50) | MAP4K4OPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL1775506 | 0.79 | LMNA (0.56) | MAP4K4HRH4HRH3 | |
| SCHEMBL6023882 | 0.79 | LMNA (0.56) | MAP4K4HRH4HRH3 | |
| SCHEMBL5076739 | 0.79 | LMNA (0.56) | MAP4K4HRH4HRH3 | |
| SCHEMBL1750255 | 0.78 | MAP4K4 (0.50) | MAP4K4OPRD1CHRM4BTKMCHR1 | |
| SCHEMBL528447 | 0.78 | MAP4K4 (0.50) | MAP4K4OPRD1CHRM4BTKMCHR1 | |
| SCHEMBL1749517 | 0.75 | NOTUM (0.41) | MAP4K4OPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL1750528 | 0.74 | MAP4K4 (0.43) | MAP4K4OPRD1CHRM4BTKJAK1 | |
| SCHEMBL4886210 | 0.73 | MAP4K4 (0.45) | MAP4K4CHRM4JAK2MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | CYP11B2, CYP11B1, CYP1A1 | MAP4K4 1267/4885P2RX7 287/4885OPRM1 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.